Opko Health Inc. (NASDAQ:OPK) CEO Phillip Md Et Al Frost purchased 78,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were purchased at an average cost of $4.22 per share, with a total value of $329,160.00. Following the acquisition, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $12,950,973.22. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Phillip Md Et Al Frost also recently made the following trade(s):

  • On Monday, February 5th, Phillip Md Et Al Frost purchased 50,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.14 per share, with a total value of $207,000.00.
  • On Friday, February 2nd, Phillip Md Et Al Frost purchased 55,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.30 per share, with a total value of $236,500.00.
  • On Wednesday, January 31st, Phillip Md Et Al Frost purchased 65,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.47 per share, with a total value of $290,550.00.
  • On Friday, January 26th, Phillip Md Et Al Frost purchased 55,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.90 per share, with a total value of $269,500.00.
  • On Wednesday, January 24th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.89 per share, with a total value of $489,000.00.
  • On Monday, January 22nd, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $4.40 per share, with a total value of $440,000.00.

Opko Health Inc. (NASDAQ:OPK) opened at $3.88 on Friday. The stock has a market cap of $2,090.00, a P/E ratio of -20.42 and a beta of 1.42. Opko Health Inc. has a 12-month low of $3.61 and a 12-month high of $8.92. The company has a current ratio of 1.66, a quick ratio of 1.48 and a debt-to-equity ratio of 0.01.

OPK has been the subject of a number of recent analyst reports. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a report on Wednesday, January 24th. BidaskClub cut shares of Opko Health from a “sell” rating to a “strong sell” rating in a research report on Friday, February 2nd. Finally, Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a research report on Wednesday, October 25th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. Opko Health currently has a consensus rating of “Hold” and an average target price of $13.34.

A number of hedge funds have recently added to or reduced their stakes in OPK. Dimensional Fund Advisors LP increased its position in Opko Health by 127.2% during the 3rd quarter. Dimensional Fund Advisors LP now owns 4,003,643 shares of the biotechnology company’s stock worth $27,466,000 after purchasing an additional 2,241,103 shares in the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in Opko Health by 611.8% during the 3rd quarter. Cornerstone Capital Management Holdings LLC. now owns 1,445,310 shares of the biotechnology company’s stock worth $9,913,000 after purchasing an additional 1,242,272 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. increased its position in Opko Health by 83.7% during the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 2,579,950 shares of the biotechnology company’s stock worth $17,698,000 after purchasing an additional 1,175,726 shares in the last quarter. IFP Advisors Inc increased its position in Opko Health by 37.1% during the 4th quarter. IFP Advisors Inc now owns 1,963,601 shares of the biotechnology company’s stock worth $9,622,000 after purchasing an additional 531,088 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in Opko Health by 43.0% during the 3rd quarter. Schwab Charles Investment Management Inc. now owns 1,566,433 shares of the biotechnology company’s stock worth $10,746,000 after purchasing an additional 471,256 shares in the last quarter. Institutional investors and hedge funds own 22.94% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Phillip Md Et Al Frost Purchases 78,000 Shares of Opko Health Inc. (OPK) Stock” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright & trademark law. The original version of this piece of content can be read at https://theolympiareport.com/2018/02/11/phillip-md-et-al-frost-purchases-78000-shares-of-opko-health-inc-opk-stock.html.

Opko Health Company Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.